Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT05682482

LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.

Led by M. Medici · Updated on 2025-02-26

600

Participants Needed

19

Research Sites

273 weeks

Total Duration

On this page

Sponsors

M

M. Medici

Lead Sponsor

Z

ZonMw: The Netherlands Organisation for Health Research and Development

Collaborating Sponsor

AI-Summary

What this Trial Is About

Hypothyroidism is common, affecting 5% of the general population, for which levothyroxine (LT4) monotherapy is the standard treatment. Despite normalized serum thyroid hormone levels, 10-15% of LT4 treated patients have various persistent complaints, the most important of which is tiredness. This could be explained by the fact that physiological T4/T3 ratios cannot be reached with LT4 monotherapy, as in a healthy individual T3 is not only derived from T4/T3 conversion but is also directly produced by the thyroid itself. Studies have reported contradicting results as to whether addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy is effective or not. Studies have suggested higher effectiveness in patients carrying genetic variation in the type 2 deiodinase (DIO2-rs225014) and monocarboxylate transporter 10 (MCT10-rs17606253) genes. Objective: To investigate whether addition of liothyronine (LT4/LT3 combination therapy) in in patients with persistent tiredness on LT4 monotherapy is effective or not in relieving tiredness.

CONDITIONS

Official Title

LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with overt or subclinical primary hypothyroidism aged 18 years or older
  • LT4 monotherapy for at least 6 months
  • LT4 dose between 75-225 micrograms, with at least 1.2 micrograms per kilogram
  • TSH levels within the normal assay-specific range for at least 3 months
  • Severe tiredness greatly impacting daily life for at least 6 months, based on patient's own experience
  • Sufficient fluency in Dutch and ability to read Dutch
Not Eligible

You will not qualify if you...

  • Congenital hypothyroidism, hypothyroidism after (sub)acute thyroiditis, or secondary (central) hypothyroidism
  • History of thyroid surgery, radioactive iodine treatment, or head/neck radiotherapy
  • Current or past use of thyroid interfering drugs such as amiodarone, immunotherapy, tyrosine kinase inhibitors, interferon, lithium, or current corticosteroids or dopamine
  • Current psychiatric disease treated at a specialized mental health institution (gespecialiseerde GGZ)
  • Clinical diagnosis of dementia
  • Pregnancy, breastfeeding, or planning pregnancy within 2 years
  • Women of reproductive age not using adequate contraception, not sterilized, and without a sterilized partner
  • Significant functional or structural heart abnormalities
  • Recent acute coronary syndrome or unstable angina within 4 weeks
  • Current or past atrial fibrillation
  • ECG conduction disorders (QRS >120 ms or prolonged QTc: women ≥460 ms, men ≥450 ms)
  • Frequent ventricular extrasystole or ventricular tachycardia
  • Other clear medical causes for tiredness such as end-stage renal disease, anemia, severe COPD, cancer
  • Major life events causing tiredness like mourning or job loss

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 19 locations

1

Flevoziekenhuis

Almere Stad, Netherlands

Actively Recruiting

2

Amsterdam UMC - Location AMC

Amsterdam, Netherlands

Actively Recruiting

3

Gelre ziekenhuizen

Apeldoorn, Netherlands

Not Yet Recruiting

4

Rijnstate

Arnhem, Netherlands

Actively Recruiting

5

Amphia ziekenhuis

Breda, Netherlands

Actively Recruiting

6

Van Weel-Bethesda Hospital

Dirksland, Netherlands

Actively Recruiting

7

Albert Schweitzer Hospital

Dordrecht, Netherlands

Actively Recruiting

8

Treant

Emmen, Netherlands

Not Yet Recruiting

9

Admiraal de Ruyter Hospital

Goes, Netherlands

Actively Recruiting

10

University Medical Center Groningen

Groningen, Netherlands

Actively Recruiting

11

Saxenburgh MC

Hardenberg, Netherlands

Actively Recruiting

12

Radboudumc

Nijmegen, Netherlands

Actively Recruiting

13

Erasmus Medical Center

Rotterdam, Netherlands

Actively Recruiting

14

Maasstad Hospital

Rotterdam, Netherlands

Actively Recruiting

15

Franciscus Gasthuis & Vlietland

Schiedam, Netherlands

Actively Recruiting

16

Zuyderland

Sittard, Netherlands

Actively Recruiting

17

University Medical Center Utrecht

Utrecht, Netherlands

Actively Recruiting

18

Maxima Medical Center

Veldhoven, Netherlands

Actively Recruiting

19

Vie Curie MC

Venlo, Netherlands

Not Yet Recruiting

Loading map...

Research Team

M

Marco Medici, MD PhD

CONTACT

L

Lizette Blankers, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here